Zobrazeno 71 - 80
of 560
pro vyhledávání: ''
Autor:
Jasvinder A. Singh
Publikováno v:
Annals of the rheumatic diseases. 81(7)
We appreciate the interest and comments by Quilis et al 1 on our recent publication.2 Quilis et al draw our attention to the incidence of cutaneous adverse reactions (CARs) with febuxostat in people who had already had reactions with allopurinol. In
Autor:
Laura Villarreal, W. Rivero, Diana Buitrago-Garcia, Pedro Santos-Moreno, M. Cabrera, A. Aza, Adriana Rojas-Villarraga
Publikováno v:
Repositorio Digital Institucional ReDi
Fundación Universitaria de Ciencias de la Salud-FUCS
instacron:Fundación Universitaria de Ciencias de la Salud-FUCS
Fundación Universitaria de Ciencias de la Salud-FUCS
instacron:Fundación Universitaria de Ciencias de la Salud-FUCS
We read with interest the paper of Graef et al recently published in your journal about the situation resulting from the massive use of antimalarials for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2/COVID-19), despite the fact that the
Autor:
Georg Schett, Andrea Hermina Györfi, Matthias May, Andreas E. Kremer, Marcel Vetter, Thomas Harrer, Markus Kopp, Jörg H W Distler, Michael Uder
Publikováno v:
Annals of the Rheumatic Diseases
The COVID-19 pandemic represents a challenge for rheumatologists: how activity of rheumatological diseases or disease-modifying therapies may affect the outcome of SARS-CoV-2 infection is only beginning to be understood. Gianfrancesco et al provided
Autor:
Valentina Grossi, Luca Quartuccio, Mariangela Manfredi, Arianna Damiani, Maria Infantino, Francesca Li Gobbi, Gianfranco Giannasi, Maurizio Benucci
Publikováno v:
Annals of the Rheumatic Diseases
We read the interesting epidemiological study on 600 patients with rheumatic diseases hospitalised for COVID-19 infection (COVID-19 Global Rheumatology Alliance Registry) published by Gianfrancesco et al .1 Data analysis showed a slightly increased r
Autor:
Fernando Pérez Ruiz, Neus Quilis, Eliseo Pascual, Boris Anthony Blanco Cáceres, Mariano Andrés, Francisca Sivera, Paloma Vela, Enrique Calvo-Aranda, Cesar Diaz-Torne, Alejandro Prada-Ojeda
Publikováno v:
ANNALS OF THE RHEUMATIC DISEASES
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Dear Editor, We read with interest the recent article by Singh and Cleveland on the hypersensitivity risk of allopurinol (ALP) and febuxostat (FBX) compared with colchicine.1 A common challenge when using ALP, linked to hypersensitivity reactions, is
Publikováno v:
Annals of the Rheumatic Diseases
We thank Mathian et al for reporting the outcomes of COVID-19 disease in a series of 17 patients with systemic lupus erythematosus (SLE) from several hospitals across France.1 In a context where there is substantial interest in the role of hydroxychl
Autor:
Zahir Amoura, Alexis Mathian
Publikováno v:
Annals of the Rheumatic Diseases
We thank Favalli et al for their interest in our study reporting the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of 17 patients with systemic lupus erythematosus (SLE) under long-ter
Autor:
Yaneli Juárez-Vicuña, Claudia Tavera-Alonso, Armando Vazquez-Rangel, Malinalli Brianza-Padilla, Luis M. Amezcua-Guerra, Marisol Hernández-Salas, Fausto Sánchez-Muñoz, Gustavo Rojas-Velasco, Ricardo Márquez-Velasco, Francisco M. Baranda-Tovar, Rashidi Springall, Héctor González-Pacheco
Publikováno v:
Annals of the Rheumatic Diseases
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated coagulopathy are particularly worrisome in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), as these diseases carry an
Autor:
Evelyne Vinet, Arielle Mendel, Sindhu R. Johnson, Sasha Bernatsky, Diane Lacaille, J. Carter Thorne
Publikováno v:
Annals of the Rheumatic Diseases
Across the globe, concerns of hydroxychloroquine (HCQ) supply shortages for patients with rheumatic disease are growing,1 in part as a consequence of the immense scientific and public enthusiasm for HCQ as a potential COVID-19 therapy.2 3 However, pu
Autor:
Alexis Mathian, Zahir Amoura
Publikováno v:
Annals of the Rheumatic Diseases
We thank Nikpour et al for their interest in our study reporting on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19 in a case series of 17 patients with systemic lupus erythematosus (SLE) under long-t